Developing innovative vaccines for effective disease prevention (Q78618): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Changed an Item: Fixing rounding issue)
(‎Removed claim: summary (P836): Reference_reference_programme_aids:SA.41471 (2015/X) _public:Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (OJ(OJ LEU L 187/1, 26.06.2014).The aim of the project is to develop and verify two innovative products — Salmovir Neo and Colisalmovir (vaccines for pigeons).The result of the project will...)
Property / summary
Reference_reference_programme_aids:SA.41471 (2015/X) _public:Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (OJ(OJ LEU L 187/1, 26.06.2014).The aim of the project is to develop and verify two innovative products — Salmovir Neo and Colisalmovir (vaccines for pigeons).The result of the project will be the formulation and the verified composition of these preparations, in the form and operation, as well as of the dosage, as well as of the specific manufacturing technology.The operation and efficacy of the preparations will be confirmed by a number of studies carried out in the course of the implementation of the project.At the same time, the aim of the project and the research problem is to respond to questions concerning the optimal composition, pharmaceutical form, dosage forms and manufacturing technologies of products which have so far not have their counterparts in the market.Therefore, the resulting products will in fact be innovative and the scope of the new functionalities will fully reflect the needs of the target group of these products.The project results in product innovation — in the form of new (Colissalamvir) and significantly improved (Salmovir Neo) of products — vaccines for pigeons.They will be used for the prophylaxis of paramycosis, salmonellosis and corot in pigeons.They will be preparations of a new, unprecedented composition, against diseases which have so far been lacking in vaccines (Colisalamvir).In addition, they will be based on homologous strains, which affects the most important characteristic of vaccines, i.e. immunogenicity.What is new is the range of diseases to which preparations will be protected.As mentioned, both vaccines, as multiple, will be resistant to the organism at the same time against several infectious diseases. (English)
 
Property / summary: Reference_reference_programme_aids:SA.41471 (2015/X) _public:Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (OJ(OJ LEU L 187/1, 26.06.2014).The aim of the project is to develop and verify two innovative products — Salmovir Neo and Colisalmovir (vaccines for pigeons).The result of the project will be the formulation and the verified composition of these preparations, in the form and operation, as well as of the dosage, as well as of the specific manufacturing technology.The operation and efficacy of the preparations will be confirmed by a number of studies carried out in the course of the implementation of the project.At the same time, the aim of the project and the research problem is to respond to questions concerning the optimal composition, pharmaceutical form, dosage forms and manufacturing technologies of products which have so far not have their counterparts in the market.Therefore, the resulting products will in fact be innovative and the scope of the new functionalities will fully reflect the needs of the target group of these products.The project results in product innovation — in the form of new (Colissalamvir) and significantly improved (Salmovir Neo) of products — vaccines for pigeons.They will be used for the prophylaxis of paramycosis, salmonellosis and corot in pigeons.They will be preparations of a new, unprecedented composition, against diseases which have so far been lacking in vaccines (Colisalamvir).In addition, they will be based on homologous strains, which affects the most important characteristic of vaccines, i.e. immunogenicity.What is new is the range of diseases to which preparations will be protected.As mentioned, both vaccines, as multiple, will be resistant to the organism at the same time against several infectious diseases. (English) / rank
Normal rank
 

Revision as of 14:37, 14 October 2020

Project in Poland financed by DG Regio
Language Label Description Also known as
English
Developing innovative vaccines for effective disease prevention
Project in Poland financed by DG Regio

    Statements

    country
    Poland
    0 references
    EU contribution
    1,699,118.34 zloty
    0 references
    407,788.40 Euro
    exchange rate to Euro
    0.24 Euro
    point in time
    13 January 2020
    0 references
    budget
    2,838,303.96 zloty
    0 references
    681,192.95 Euro
    exchange rate to Euro
    0.24 Euro
    point in time
    13 January 2020
    0 references
    co-financing rate
    59.86 percent
    0 references
    start time
    1 January 2016
    0 references
    end time
    31 March 2022
    0 references
    beneficiary name (string)
    "BIOWET PUŁAWY" SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
    0 references
    beneficiary
    Q2510458
    0 references
    coordinate location

    51°25'34.7"N, 21°59'7.1"E
    0 references
    summary
    Numer_referencyjny_programu_pomocowego: SA.41471(2015/X) Przeznaczenie_pomocy_publicznej: art. 25 rozporządzenia KE nr 651/2014 z dnia 17 czerwca 2014 r. uznające niektóre rodzaje pomocy za zgodne z rynkiem wewnętrznym w stosowaniu art. 107 i 108 Traktatu (Dz. Urz. UE L 187/1 z 26.06.2014). Celem projektu jest opracowanie i weryfikacja dwóch innowacyjnych produktów - Salmoviru Neo oraz Colisalmoviru (szczepionki dla gołębi). Rezultatem projektu będzie opracowany i zweryfikowany skład tych preparatów, z określoną postacią i działaniem, dawkowaniem, a także konkretną technologią wytwarzania. Działanie i skuteczność preparatów potwierdzą liczne badania prowadzone w toku realizacji projektu. Celem realizacji projektu i jednocześnie problemem badawczym jest odpowiedź na pytania dotyczące optymalnego składu, postaci farmaceutycznej, dawkowania oraz technologii wytwarzania produktów, które dotychczas nie mają swoich odpowiedników na rynku. Zatem powstałe w toku realizacji projektu produkty będą w swej istocie innowacyjne, a zakres nowych funkcjonalności w pełni odzwierciedlać będzie potrzeby grupy docelowej tych produktów. Rezultatem projektu jest innowacja produktowa –w postaci nowych (Colisalmovir) i znacząco udoskonalonych (Salmovir Neo) produktów - szczepionek dla gołębi. Będą one stosowane w immunoprofilaktyce paramyksowirozy, salmonelozy i kolibakteriozy gołębi. Będą to preparaty o nowym, niespotykanym dotychczas składzie, przeciw chorobom na które dotychczas brakowało szczepionek (Colisalmovir). Ponadto będą one oparte o homologiczne szczepy – co ma wpływ na najistotniejszą cechę szczepionek, tj. immunogenność. Nowością jest również zakres chorób, przed którymi chronić będą preparaty. Jak wspomniano obie szczepionki, jako wieloważne, będą uodparniać organizm jednocześnie przeciw kilku chorobom zakaźnym. (Polish)
    0 references

    Identifiers

    Polish Kohesio ID
    POIR.01.01.01-00-1145/15
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q78618&oldid=6347968"